ARVINAS, INC. Net Income (Loss) Available to Common Stockholders, Basic
ARVINAS, INC. (ARVN) reported Net Income (Loss) Available to Common Stockholders, Basic of -$119.33 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2021-03-01
- ARVINAS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2019-12-31 was -$21.05M.
- ARVINAS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2019-09-30 was -$17.68M.
- ARVINAS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2019-06-30 was -$17.16M.
- ARVINAS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2019-03-31 was -$14.40M.
- ARVINAS, INC. net income (loss) available to common stockholders, basic for fiscal 2020 was -$119.33M.
- ARVINAS, INC. net income (loss) available to common stockholders, basic for fiscal 2019 was -$70.29M.
- ARVINAS, INC. net income (loss) available to common stockholders, basic for fiscal 2018 was -$239.85M.
- ARVINAS, INC. net income (loss) available to common stockholders, basic for fiscal 2017 was -$28.62M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$119.33M 10-K · filed 2021-03-01 | |||
| 2019-12-31 | -$21.05M 10-K · filed 2020-03-16 | -$38.72M derived: sum of 2 quarters · filed 2020-03-16 | -$55.89M derived: sum of 3 quarters · filed 2020-03-16 | -$70.29M 10-K · filed 2021-03-01 |
| 2019-09-30 | -$17.68M 10-K · filed 2020-03-16 | -$34.84M derived: sum of 2 quarters · filed 2020-03-16 | -$49.24M 10-Q · filed 2019-11-04 | -$65.33M derived: sum of 4 quarters · filed 2020-03-16 |
| 2019-06-30 | -$17.16M 10-K · filed 2020-03-16 | -$31.57M 10-Q · filed 2019-08-05 | -$47.66M derived: sum of 3 quarters · filed 2020-03-16 | -$173.10M derived: sum of 4 quarters · filed 2020-03-16 |
| 2019-03-31 | -$14.40M 10-K · filed 2020-03-16 | -$30.49M derived: sum of 2 quarters · filed 2020-03-16 | -$155.93M derived: sum of 3 quarters · filed 2020-03-16 | -$178.62M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-12-31 | -$16.09M 10-K · filed 2020-03-16 | -$141.53M derived: sum of 2 quarters · filed 2020-03-16 | -$164.21M derived: sum of 3 quarters · filed 2020-03-16 | -$239.85M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$125.44M 10-K · filed 2020-03-16 | -$148.13M derived: sum of 2 quarters · filed 2020-03-16 | -$223.76M 10-Q · filed 2019-11-04 | -$233.06M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | -$22.69M 10-K · filed 2020-03-16 | -$98.32M 10-Q · filed 2019-08-05 | -$107.62M derived: sum of 3 quarters · filed 2020-03-16 | -$114.02M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-03-31 | -$75.63M 10-K · filed 2020-03-16 | -$84.93M derived: sum of 2 quarters · filed 2020-03-16 | -$91.33M derived: sum of 3 quarters · filed 2020-03-16 | -$98.01M derived: sum of 4 quarters · filed 2020-03-16 |
| 2017-12-31 | -$9.30M 10-K · filed 2019-03-26 | -$15.70M derived: sum of 2 quarters · filed 2019-03-26 | -$22.37M derived: sum of 3 quarters · filed 2019-03-26 | -$28.62M 10-K · filed 2019-03-26 |
| 2017-09-30 | -$6.40M 10-K · filed 2019-03-26 | -$13.08M derived: sum of 2 quarters · filed 2019-03-26 | -$19.32M 10-Q · filed 2018-11-14 | |
| 2017-06-30 | -$6.68M 10-K · filed 2019-03-26 | -$12.92M derived: sum of 2 quarters · filed 2019-03-26 | ||
| 2017-03-31 | -$6.25M 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |